Ivy Brain Tumor Center Opens New Clinical Trial for Patients with Recurrent Grade IV Gliomas

The Ivy Brain Tumor Center at Barrow Neurological Institute announced the opening of a new Phase 0/Ib clinical trial to evaluate AZD1390, an Ataxia telangiectasia mutant kinase inhibitor being developed by AstraZeneca, in patients with recurrent grade IV gliomas.